Explore

TrendlineTrendline
Bluejay Diagnostics Establishes Manufacturing Site in Japan, Fulfilling Toray Agreement Milestone

Bluejay Diagnostics Establishes Manufacturing Site in Japan, Fulfilling Toray Agreement Milestone

Bluejay Diagnostics Establishes Manufacturing Site in Japan, Fulfilling Toray Agreement Milestone
TrendlineTrendline
Novo Nordisk Faces FDA Delay for Hemophilia Drug, Shifts Focus to Obesity and Metabolic Therapies

Novo Nordisk Faces FDA Delay for Hemophilia Drug, Shifts Focus to Obesity and Metabolic Therapies

Novo Nordisk Faces FDA Delay for Hemophilia Drug, Shifts Focus to Obesity and Metabolic Therapies
Rapid ReadRapid Read
RingConn Smart Ring Receives FDA 510(k) Clearance for Non-Invasive Blood Oxygen Monitoring in U.S. Market

RingConn Smart Ring Receives FDA 510(k) Clearance for Non-Invasive Blood Oxygen Monitoring in U.S. Market

Shenzhen Ninenovo Technology Limited, the parent company of RingConn, has announced that its Smart Ring has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA). This clearance specifically pertains to the non-invasive measurement of blood oxygen (SpO2) using the device. The FDA's determination signifies that the RingConn Smart Ring is substantially equivalent to legally marketed predicate devices for this function. This regulatory approval is a significant step for RingConn, enabling its expansion into the U.S. healthcare and wellness market. The device utilizes PPG sensor technology to integrate professional-grade blood oxygen monitoring capabilities into a wearable form factor. RingConn is also actively engaged in ongoing clinical research to further validate its blood oxygen monitoring data. The company has previously obtained various international certifications, including EU CE, U.S. FCC, Japan MIC, UK UKCA, and Australia RCM, and its product is available in over 190 countries an...
ReutersReuters
J&J posts weak medical device sales, shares fall

J&J posts weak medical device sales, shares fall

By Michael Erman and Sriparna Roy Oct 13 (Reuters) - Johnson & Johnson reported sales in its medical devices business on Tuesday that fell short of Wall Street expectations, citing geopolitical issues including the Middle East conflict, and its shares fell more than 6%.
TrendlineTrendline
FDA Authorizes Microneedling for Specific Uses, Warns Against At-Home Devices and Unapproved Combinations

FDA Authorizes Microneedling for Specific Uses, Warns Against At-Home Devices and Unapproved Combinations

FDA Authorizes Microneedling for Specific Uses, Warns Against At-Home Devices and Unapproved Combinations
Rapid ReadRapid Read
FDA Approves First Once-Monthly Subcutaneous Olanzapine Injection for Schizophrenia

FDA Approves First Once-Monthly Subcutaneous Olanzapine Injection for Schizophrenia

The U.S. Food and Drug Administration (FDA) has granted approval for Weltruza (olanzapine extended-release injectable suspension), marking it as the first and only once-monthly subcutaneous injectable olanzapine for adults diagnosed with schizophrenia. This new formulation offers doses of 318 mg, 425 mg, and 531 mg, which correspond to daily oral olanzapine doses of 10 mg, 15 mg, and 20 mg, respectively. The approval was based on the positive results from the phase 3 SOLARIS trial. This trial involved 675 adults, aged 18 to 64, who were randomized over an 8-week period to receive one of three monthly doses or a placebo. The study demonstrated statistically significant symptom improvement in patients receiving Weltruza compared to those on placebo. Teva, the manufacturer, highlighted that this product eliminates the need for loading doses, oral supplementation, or post-injection monitoring, a common requirement for other extended-release olanzapine formulations.
ReutersReuters
J&J beats earnings estimates; Middle East conflict weighs on medical device sales

J&J beats earnings estimates; Middle East conflict weighs on medical device sales

By Michael Erman Oct 13 (Reuters) - Johnson & Johnson reported a slightly higher-than-expected profit on Tuesday, driven by strong sales of immune disease treatment Tremfya, but geopolitical issues including the Middle East conflict were a drag on its medical devices business.
Rapid ReadRapid Read
CervoMed Reports Positive Biomarker Results in Phase 2a Trial for Nonfluent Variant Primary Progressive Aphasia

CervoMed Reports Positive Biomarker Results in Phase 2a Trial for Nonfluent Variant Primary Progressive Aphasia

CervoMed Inc. announced initial positive results from the open-label portion of its Phase 2a clinical trial for neflamapimod, a drug targeting nonfluent variant primary progressive aphasia (nfvPPA). The data, presented at the 15th International Society of Frontotemporal Dementias (ISFTD) Annual Meeting, showed a reduction in mean plasma levels of neurofilament light chain (NfL), a key biomarker indicating neuronal damage and degeneration, over the first 12 weeks of treatment. The reduction was more pronounced in participants with higher baseline NfL levels. NfvPPA is a rare, progressive form of dementia characterized by speech difficulties, and currently, there are no approved pharmacological treatments in the United States or European Union. Neflamapimod is an investigational, orally administered small-molecule drug that inhibits the alpha isoform of p38 MAP kinase, an enzyme involved in neuroinflammation and synaptic dysfunction.
Rapid ReadRapid Read
FDA Has Not Approved Enclomiphene for Any Indication, Raising Regulatory Concerns for Unapproved Testosterone Alternative

FDA Has Not Approved Enclomiphene for Any Indication, Raising Regulatory Concerns for Unapproved Testosterone Alternative

Enclomiphene, an oral selective estrogen receptor modulator, is being discussed as an alternative to Testosterone Replacement Therapy (TRT) for men with low testosterone, particularly those wishing to preserve fertility. Unlike TRT, which introduces external testosterone, enclomiphene works by blocking estrogen feedback in the brain, thereby stimulating the body's own testes to produce more testosterone, as well as luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Clinical trials have shown that enclomiphene can raise total testosterone levels into the normal range and maintain sperm concentration, whereas TRT typically suppresses sperm production. However, the U.S. Food and Drug Administration (FDA) has not approved enclomiphene for any indication, issuing a complete response letter in late 2015. The FDA's decision was based on concerns that the application did not sufficiently demonstrate a clinical benefit that patients could feel or measure, and questioned whether secondary hypogonadism ...
TrendlineTrendline
Starbucks Faces Federal Lawsuit Over 'Sugar-Free' Drink Claims

Starbucks Faces Federal Lawsuit Over 'Sugar-Free' Drink Claims

Starbucks Faces Federal Lawsuit Over 'Sugar-Free' Drink Claims
TrendlineTrendline
FDA Policy Insights Guide AI Compliance in Life Sciences

FDA Policy Insights Guide AI Compliance in Life Sciences

FDA Policy Insights Guide AI Compliance in Life Sciences
Westchester County Journal NewsWestchester County Journal News
Check your fridge for these recalled Gatorade drinks

Check your fridge for these recalled Gatorade drinks

Over 120,000 cases of Gatorade are recalled in 37 states because they contain undeclared food coloring.